Stock Events

Stock Events

Xenon Pharmaceuticals 

$57.91
26
+$0.2+0.35% Today

Statistics

Day High
58.2
Day Low
57.6
52W High
62.76
52W Low
28.49
Volume
110,467
Avg. Volume
-
Mkt Cap
4.63B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-1.31
-1.14
-0.98
-0.81
Expected EPS
-1.179498
Actual EPS
N/A

Financials

-4,612.13%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
15MRevenue
-691.82MNet Income

Analyst Ratings

74.25Average Price Target
The highest estimate is 97.00.
From 8 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow XENE. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap107.83B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for genetic diseases, similar to Xenon's focus on neurological disorders.
Biogen
BIIB
Mkt Cap27.62B
Biogen competes in the neurological disorder space, particularly in developing therapies for diseases like multiple sclerosis and Alzheimer's, overlapping with Xenon's target market.
Alkermes
ALKS
Mkt Cap5.69B
Alkermes competes with Xenon in developing treatments for central nervous system (CNS) disorders, including schizophrenia and bipolar disorder.
Ionis Pharmaceuticals
IONS
Mkt Cap12.44B
Ionis Pharmaceuticals is a competitor due to its focus on RNA-targeted drug discovery for neurological diseases, a similar area of interest as Xenon.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.76B
ACADIA Pharmaceuticals targets the CNS disorder market, with a focus on psychosis and schizophrenia treatments, areas that overlap with Xenon's research interests.
AMGEN
AMGN
Mkt Cap178B
Amgen, with its broad focus on biotechnological therapies for various conditions, competes indirectly with Xenon through its investments in neuroscience and neurodegenerative diseases.
PTC Therapeutics
PTCT
Mkt Cap5.43B
PTC Therapeutics operates in the space of rare diseases, including neurological disorders, making it a competitor to Xenon's specialized focus.
CRISPR Therapeutics
CRSP
Mkt Cap4.98B
CRISPR Therapeutics is involved in gene editing, a technology that has the potential to treat genetic disorders, competing with Xenon's approach to drug development.

About

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Show more...
CEO
Mr. Thomas Patrick Kelly J.D.
Employees
316
Country
Canada
ISIN
CA98420N1050

Listings

STU
DE
XP0.STU
MU
DE
XP0.MU
XNAS
US
XENE
F
DE
XP0.F

0 Comments

Share your thoughts

FAQ

What is Xenon Pharmaceuticals stock price today?▼
The current price of XENE is $57.91 USD — it has increased by +0.35% in the past 24 hours. Watch Xenon Pharmaceuticals stock price performance more closely on the chart.
What is Xenon Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Xenon Pharmaceuticals stocks are traded under the ticker XENE.
Is Xenon Pharmaceuticals stock price growing?▼
XENE stock has risen by +3.86% compared to the previous week, the month change is a +1.86% rise, over the last year Xenon Pharmaceuticals has showed a +64.58% increase.
What is Xenon Pharmaceuticals market cap?▼
Today Xenon Pharmaceuticals has the market capitalization of 4.63B
When is the next Xenon Pharmaceuticals earnings date?▼
Xenon Pharmaceuticals is going to release the next earnings report on May 07, 2026.
What were Xenon Pharmaceuticals earnings last quarter?▼
XENE earnings for the last quarter are -1.31 USD per share, whereas the estimation was -1.19 USD resulting in a -9.94% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Xenon Pharmaceuticals revenue for the last year?▼
Xenon Pharmaceuticals revenue for the last year amounts to 15M USD.
What is Xenon Pharmaceuticals net income for the last year?▼
XENE net income for the last year is -691.82M USD.
How many employees does Xenon Pharmaceuticals have?▼
As of May 06, 2026, the company has 316 employees.
In which sector is Xenon Pharmaceuticals located?▼
Xenon Pharmaceuticals operates in the Health & Wellness sector.
When did Xenon Pharmaceuticals complete a stock split?▼
Xenon Pharmaceuticals has not had any recent stock splits.
Where is Xenon Pharmaceuticals headquartered?▼
Xenon Pharmaceuticals is headquartered in Burnaby, Canada.